These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19577811)

  • 1. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
    Tegla CA; Cudrici C; Rus V; Ito T; Vlaicu S; Singh A; Rus H
    J Neuroimmunol; 2009 Aug; 213(1-2):3-11. PubMed ID: 19577811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F; Shin ML
    J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F
    Ann Med; 2005; 37(2):97-104. PubMed ID: 16026117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement.
    Cudrici C; Niculescu T; Niculescu F; Shin ML; Rus H
    J Rehabil Res Dev; 2006; 43(1):123-32. PubMed ID: 16847778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
    Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H
    J Immunol; 2004 May; 172(9):5702-6. PubMed ID: 15100315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS.
    Reynolds R; Dawson M; Papadopoulos D; Polito A; Di Bello IC; Pham-Dinh D; Levine J
    J Neurocytol; 2002; 31(6-7):523-36. PubMed ID: 14501221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination.
    Loda E; Balabanov R
    Rev Neurosci; 2012 Jan; 23(2):145-52. PubMed ID: 22499673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
    Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
    Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
    Mc Guire C; Volckaert T; Wolke U; Sze M; de Rycke R; Waisman A; Prinz M; Beyaert R; Pasparakis M; van Loo G
    J Immunol; 2010 Dec; 185(12):7646-53. PubMed ID: 21068410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models.
    Rajendran R; Böttiger G; Stadelmann C; Karnati S; Berghoff M
    Cells; 2021 Apr; 10(4):. PubMed ID: 33924474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
    Khalaj AJ; Hasselmann J; Augello C; Moore S; Tiwari-Woodruff SK
    J Steroid Biochem Mol Biol; 2016 Jun; 160():43-52. PubMed ID: 26776441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligodendrocyte-Specific Deletion of
    Rajendran R; Rajendran V; Giraldo-Velasquez M; Megalofonou FF; Gurski F; Stadelmann C; Karnati S; Berghoff M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F
    Adv Exp Med Biol; 2006; 586():139-51. PubMed ID: 16893070
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis.
    LeVine SM; Chakrabarty A
    Ann N Y Acad Sci; 2004 Mar; 1012():252-66. PubMed ID: 15105271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
    Stoffels JM; de Jonge JC; Stancic M; Nomden A; van Strien ME; Ma D; Sisková Z; Maier O; Ffrench-Constant C; Franklin RJ; Hoekstra D; Zhao C; Baron W
    Brain; 2013 Jan; 136(Pt 1):116-31. PubMed ID: 23365094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.
    Kerstetter AE; Padovani-Claudio DA; Bai L; Miller RH
    Exp Neurol; 2009 Nov; 220(1):44-56. PubMed ID: 19616545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
    Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
    Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
    Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
    PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2007 May; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.
    Liu Y; Given KS; Harlow DE; Matschulat AM; Macklin WB; Bennett JL; Owens GP
    Acta Neuropathol Commun; 2017 Mar; 5(1):25. PubMed ID: 28340598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.